---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-26-000088"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2026-08-05T11:41:04+00:00"
generated_at: "2026-08-05T11:45:18.087267+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports 17.3mo OS in pancreatic cancer; Q2 net loss $17.3M

## Summary
- Net loss of $17.3M ($0.27/share) in Q2 2026 vs $14.4M ($0.40/share) in Q2 2025; R&D expenses rose to $14.0M from $10.5M.
- Cash, equivalents and marketable securities $182.7M as of June 30, 2026, down from $217.0M at Dec 31, 2025; runway into 2029.
- Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer is dosing patients; over 30 study locations posted.
- Phase 2a data at ASCO showed 17.3-month median overall survival in 55 patients; 84% weight stable or gained weight at 3 months.
- Appointed Andrew Gengos as CFO; he previously served as CFO of Terns Pharmaceuticals (acquired by Merck for $6.7B).

## SEC filing metadata
- accession: 0001790340-26-000088
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2026-08-05T11:41:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/0001790340-26-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-26-000088
- JSON: https://secwatch.observer/filing/0001790340-26-000088.json
- Plain text: https://secwatch.observer/filing/0001790340-26-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.